Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company

Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance

Fineline Cube Oct 20, 2022

With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...

Company Policy / Regulatory

Shaanxi Releases Notice for Inter-Provincial Orthodontic Brackets VBP

Fineline Cube Oct 20, 2022

The Shaanxi Public Resources Trading Center has released the “Inter-provincial Alliance (regions, Corps) Orthodontic Brackets...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Sweden for CMV Retinitis

Fineline Cube Oct 20, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving technical review approval from...

Company Drug

Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency

Fineline Cube Oct 20, 2022

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...

Company Deals

Kactus Biosystems Raises RMB 200M in Series B Financing for Protein and Enzyme Development

Fineline Cube Oct 20, 2022

Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has raised RMB...

Company Deals

Shandong Junxiu Biotechnology Secures RMB 45M in Series B Financing

Fineline Cube Oct 20, 2022

Shandong Junxiu Biotechnology Co., Ltd, a China-based maker of implantable regenerative medicine devices, has raised...

Company Drug

Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778

Fineline Cube Oct 20, 2022

China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I...

Company

Bayer to Set Up Shenzhen Unit to Boost Women’s Healthcare in South China

Fineline Cube Oct 19, 2022

Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to...

Company Drug

GenScript’s Legend Biotech Reports USD 55M in Carvykti Sales

Fineline Cube Oct 19, 2022

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that sales of...

Company Drug

YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval

Fineline Cube Oct 19, 2022

China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...

Company Drug

Henlius Biotech’s Hanbeitai Gains NMPA Approval for Recurrent Glioblastoma

Fineline Cube Oct 19, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Company Policy / Regulatory

NHSA Responds to Proposal on Dental Implants’ Inclusion in NRDL

Fineline Cube Oct 19, 2022

The National Healthcare Security Administration (NHSA) has responded to the No. 6184 suggestion from the...

Company

Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance

Fineline Cube Oct 19, 2022

US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing...

Company Deals

Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion

Fineline Cube Oct 19, 2022

China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO)...

Company Drug

Mabwell Bioscience’s 9MW3011 Accepted for Review by China’s NMPA

Fineline Cube Oct 19, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that its clinical filing for...

Company Drug

Zhiyi Biotechnology Receives FDA Clearance for SK10 in Chemotherapy-Induced Diarrhea

Fineline Cube Oct 19, 2022

Guangzhou-based Zhiyi Biotechnology has announced receiving clearance from the US FDA for a clinical study...

Company Deals

Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion

Fineline Cube Oct 19, 2022

Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial...

Company Deals

Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy

Fineline Cube Oct 18, 2022

Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...

Company Drug

Abogen Biosciences Receives UAE Clinical Trial Approval for Omicron BA.4/5 mRNA Vaccine

Fineline Cube Oct 18, 2022

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, has announced...

Company Deals

Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion

Fineline Cube Oct 18, 2022

Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised...

Posts pagination

1 … 550 551 552 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.